Clinical Trial Update: Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of dasatinib in acral lentiginous, mucosal, or chronic sun-damaged melanoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Lentiginous Melanoma
• Melanoma
• Mucosal Melanoma
• Sun-damaged Melanoma

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2016-09-05